Results 201 to 210 of about 1,040,359 (356)
Background/Aims Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate‐lowering therapy in people with asymptomatic hyperuricemia.
Nicola Dalbeth +19 more
wiley +1 more source
Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms [PDF]
James Mittra
openalex +1 more source
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart +14 more
wiley +1 more source
Objective We aimed to compare clinical outcomes between patients in the Allegheny Health Network rheumatoid arthritis (RA) care pathway and patients receiving usual care. Methods The care pathway initiative implements guideline‐based best practice alongside multi‐disciplinary team‐based care. Clinical and insurance claims data were extracted to compare
Tarun Sharma +7 more
wiley +1 more source
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against NSAID use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal trends in prescription NSAID and ...
Adam S. Mayer +5 more
wiley +1 more source
Corrigendum to "Treatment of hemophilic arthropathy by immunomodulatory extracellular vesicle delivered by liposome hybrid nanoparticles" [Bioact. Mater. 40 (2024) 47-63]. [PDF]
Wang D +10 more
europepmc +1 more source
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response.
Andrea Fava +26 more
wiley +1 more source

